Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Camrelizumab plus
chemotherapy as neoadjuvant therapy and Camrelizumab as adjuvant therapy in participants who
have triple negative breast cancer (TNBC).